ZVRA has 36-month beta value of 1.95. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZVRA is 52.30M, and currently, short sellers hold a 7.53% ratio of that float. The average trading volume of ZVRA on November 14, 2024 was 854.92K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ZVRA) stock’s latest price update
Zevra Therapeutics Inc (NASDAQ: ZVRA) has experienced a rise in its stock price by 1.05 compared to its previous closing price of 8.57. However, the company has seen a fall of -1.70% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-13 that Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Nichol Ochsner – VP, IR & Corporate Communications Neil McFarlane – President & CEO LaDuane Clifton – CFO Joshua Schafer – Chief Commercial Officer & EVP, Business Development Conference Call Participants Jason Butler – JMP Securities Louise Chen – Cantor Fitzgerald Samantha Corwin – William Blair Eddie Hickman – Guggenheim Securities Sumant Kulkarni – Canaccord Genuity Oren Livnat – H.C. Wainwright Operator Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.
ZVRA’s Market Performance
Zevra Therapeutics Inc (ZVRA) has seen a -1.70% fall in stock performance for the week, with a 3.34% gain in the past month and a 21.46% surge in the past quarter. The volatility ratio for the week is 6.58%, and the volatility levels for the past 30 days are at 4.95% for ZVRA. The simple moving average for the last 20 days is 2.59% for ZVRA’s stock, with a simple moving average of 38.64% for the last 200 days.
Analysts’ Opinion of ZVRA
Many brokerage firms have already submitted their reports for ZVRA stocks, with Guggenheim repeating the rating for ZVRA by listing it as a “Buy.” The predicted price for ZVRA in the upcoming period, according to Guggenheim is $20 based on the research report published on October 07, 2024 of the current year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ZVRA reach a price target of $25, previously predicting the price at $18. The rating they have provided for ZVRA stocks is “Buy” according to the report published on September 24th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to ZVRA, setting the target price at $17 in the report published on September 24th of the current year.
ZVRA Trading at 8.68% from the 50-Day Moving Average
After a stumble in the market that brought ZVRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.69% of loss for the given period.
Volatility was left at 4.95%, however, over the last 30 days, the volatility rate increased by 6.58%, as shares surge +2.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.45% upper at present.
During the last 5 trading sessions, ZVRA fell by -1.70%, which changed the moving average for the period of 200-days by +40.36% in comparison to the 20-day moving average, which settled at $8.44. In addition, Zevra Therapeutics Inc saw 32.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZVRA starting from Watton Corey Michael, who purchase 500 shares at the price of $7.92 back on Oct 11 ’24. After this action, Watton Corey Michael now owns 1,500 shares of Zevra Therapeutics Inc, valued at $3,958 using the latest closing price.
Clifton R. LaDuane, the CFO & Treasurer of Zevra Therapeutics Inc, purchase 2,000 shares at $6.77 during a trade that took place back on Jul 17 ’24, which means that Clifton R. LaDuane is holding 18,469 shares at $13,540 based on the most recent closing price.
Stock Fundamentals for ZVRA
Current profitability levels for the company are sitting at:
- -3.48 for the present operating margin
- 0.52 for the gross margin
The net margin for Zevra Therapeutics Inc stands at -3.43. The total capital return value is set at -0.55. Equity return is now at value -130.22, with -52.61 for asset returns.
Based on Zevra Therapeutics Inc (ZVRA), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -1.16. The debt to equity ratio resting at 0.86. The interest coverage ratio of the stock is -66.92.
Currently, EBITDA for the company is -48.6 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 18.62. The receivables turnover for the company is 3.18for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
To put it simply, Zevra Therapeutics Inc (ZVRA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
